Compare BTGO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTGO | EVO |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | Germany |
| Employees | 603 | 4553 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 961.8M | 934.1M |
| IPO Year | N/A | N/A |
| Metric | BTGO | EVO |
|---|---|---|
| Price | $8.95 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $14.83 | $7.00 |
| AVG Volume (30 Days) | ★ 521.3K | 94.1K |
| Earning Date | 05-13-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $34.41 | $10.05 |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.25 | $2.31 |
| 52 Week High | $15.30 | $4.80 |
| Indicator | BTGO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 36.25 |
| Support Level | $7.25 | $2.32 |
| Resistance Level | $12.11 | $3.78 |
| Average True Range (ATR) | 0.84 | 0.09 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 5.61 | 6.44 |
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.